International Journal of Radiation Oncology*Biology*Physics · 2023 · 19 citations · 32 references
MedicineRadiation OncologyUrologyUrogenital SurgeryUrologic OncologyUrologic SurgeryErectile DysfunctionProstate CancerProstate Disease ComplicationsProstate SurgeryRadiation TherapyRadiation Therapy For Prostate DiseaseMale Sexual FunctionPenile Cancer RadiotherapyPenile-sparing TherapyPostoperative Erectile DysfunctionProstatic UrethraRadiation Dose ManagementRadiation Dose ReductionSexual Function Preservation
PurposeErectile dysfunction (ED) is a common side effect after prostate cancer stereotactic body radiotherapy (SBRT). We aimed to assess the correlation between the dose to the penile bulb (PB), internal pudendal arteries (IPA), and crura with the development of ED after ultra-hypofractionation as part of a phase II clinical trial of urethra-sparing prostate SBRT.Material and methodsAmong the 170 patients with localized prostate cancer from 9 centers included in the trial, 90 men with CTCAE v4.03 grade 0-1 ED (ED-) at baseline treated with 36.25Gy in 5 fractions were selected for the present analysis. Doses delivered to the PB, crura, and IPA were analyzed and correlated with grade 2-3 ED (ED+) development. The impact on QoL assessed by the EORTC PR-25 questionnaire was reported.ResultsAfter a median follow-up of 6.5 years, 43% (n=39) of the patients developed ED+, while 57% (n=51) remained ED-. The dose delivered to the crura was significantly higher in ED+ patients than in ED- patients (7.7 Gy vs 3.6 Gy (p=0.014) for the Dmean and 18.5 Gy vs 7.2 Gy (p=0.015) for the D2%, respectively). No statistically significant difference between ED+ and ED- patients was observed for the dose delivered to the PB and the IPA. The median ED+ free-survival was worse in patients receiving a crura Dmean ≥ 4.7 Gy vs < 4.7 Gy (51.5% vs 71.7%, p=0.005), and a crura D2% >12 Gy vs ≤ 12 Gy (54.9% vs 68.9%, p =0.015). No ED+ free-survival differences were observed for doses delivered to PB and IPA. Decline in EORTC PR-25 sexual functioning was significantly more pronounced in patients with higher doses to the crura.ConclusionsBy keeping a Dmean and D2% to crura below 4.7 Gy and 12 Gy respectively, the risk to develop ED+ following prostate SBRT may be significantly reduced.
32
Interpreting the significance of changes in health-related quality-of-life scores.
David Osoba, George Rodrigues, James D. Myles et al. · Journal of Clinical Oncology · 1998 · 2.9K citations
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
Martin G. Sanda, Rodney L. Dunn, Jeff M. Michalski et al. · New England Journal of Medicine · 2008 · 2.3K citations · Full text
Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman et al. · The Lancet · 2019 · 871 citations